Valeant wraps up its $11B Salix buyout; Bayer touts Eylea data from China;

@FiercePharma: Teva used kickbacks to boost Copaxone, Azilect scripts, feds say. FiercePharmaMarketing article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharma: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Story | Follow @EricPFierce

@CarlyHFierce: Final Four time: Four names, one crown: Trulicity, Vimizim star in the #FierceMadness Final Four push. Vote! | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) wrapped up its $11 million buyout of the specialty drugmaker Salix Pharmaceuticals, grabbing that company's gastrointestinal drug portfolio in the process. Report

> Bayer said new study results from China show that Eylea works to improve vision in patients with wet age-related macular degeneration; the German drugmaker has asked regulators there to approve the med for that use. Report

> AstraZeneca ($AZN) started razing 450,000 square feet of former laboratory space at its North American headquarters in Delaware. Report

> A federal judge denied attempts by Millennium, Merck ($MRK) and Merck's Schering-Plough unit to nix kickback allegations in a whistleblower lawsuit over the drug Integrilin. Report

> Sanofi ($SNY) persuaded a U.S. judge to drop part of a whistleblower complaint against the company, but will have to face the rest of the off-label marketing suit. Report

Medical Device News

@FierceMedDev: Hansen eyes expansion for robotic surgery system with Chinese distribution deal. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics, feat. 23andMe's first foray into retail, $DGX and $Q's JV, and more. Issue | Follow @EmilyWFierce

> Sony sells off half its Olympus stake amid duodenoscope pushback. Report

> World's largest orthopedics contract manufacturer closing two plants. Story

> Orthofix restates earnings, gains option to buy migraine device startup eNeura for $65M. More

> Boston Scientific recalls its Expel biliary catheters after complaints of fragmentation. Article

Biotech News

@FierceBiotech: Prepping for a Duchenne study, Catabasis banks $12.4M in new fundraising. News | Follow @FierceBiotech

@JohnCFierce: Yale team says failed AstraZeneca drug shows promise in Alzheimer's. FierceBiotechResearch story | Follow @JohnCFierce

@DamianFierce: Serious question: Is the $SRPT hold muzak an instrumental of "I'm all out of love / I'm so lost without you?" | Follow @DamianFierce

> Roche CEO Schwan flags more biopharma partnering ahead. More

> Calico sheds light on its R&D mission with UCSF partnership. Report

> VC heavyweights back a $150M NYC biotech fund with Lilly and Celgene in tow. Article

Biotech Research News

> IL-17 may guard against skin infections in alcoholics. More

> Google-backed Calico in-licenses UCSF scientist's work on cognition. Report

> Professional societies flag key areas for COPD research. Item

> Yale team says failed AstraZeneca drug shows promise in Alzheimer's. Story

> Michigan investigators improve on a new approach to acute leukemia. Article

Diagnostics News

> Quest and Quintiles team up for JV aimed at clinical research, diagnostics. News

> White House calls for advancing rapid diagnostics to combat drug-resistant bacteria. More

> Bayer signs cardiovascular genomics alliance with Harvard, MIT. Report

> 23andMe dives into retail with U.K. deal for personal genome service. Story

> Cancer Dx startup Helomics joins U.K. genomics initiative alongside big biopharmas. Article

Pharma Marketing News

> Teva used kickbacks to boost Copaxone, Azilect scripts, feds say. News

> Celltrion eyes biosim Remicade launch in the U.S. this year. Item

> Vivus to slash obesity salesforce by one-third, turn to digital instead. Report

> Tiny Egalet scouting for 60 reps to hawk its new pain meds. Article

> Forget fighting over Flonase ads. GSK and J&J settle on fight for market share. Story

And Finally... How Sun Pharma CEO Dilip Shangvi became the richest Indian. Report